

Moderna COVID-19 Vaccine - Expanded emergency use authorization

- On January 7, 2022, the <u>FDA announced</u> expanded emergency use authorization (EUA) for the <u>Moderna COVID-19 vaccine</u>, a single Moderna COVID-19 vaccine booster dose (0.25 mL) may be administered at least 5 months after completing a primary series of the Moderna COVID-19 vaccine to individuals 18 years of age or older.
 - Previously, the single Moderna COVID-19 vaccine booster dose could be administered at least 6 months after completing a primary series.
- The EUA for a single booster dose of the Moderna COVID-19 vaccine at 5 months is based on shortening the length of time between completion of a primary series and a booster dose may help reduce waning immunity.
- This action also brings consistency in the timing for administration of a booster dose among the available mRNA vaccines. The Pfizer/BioNTech COVID-19 vaccine is authorized to be given as a single booster dose at least 5 months after completing a primary series.
- Below is a useful chart from the FDA that summarizes current booster authorizations for all three COVID-19 vaccines:

Which primary vaccine series did you complete?	Pfizer-BioNTech	Moderna	Janssen (J&J)
You san get a tasan r	It's been at least 5 months since completing a primary series AND you are:	It's been at least 5 months since completing a primary series AND you are:	It's been at least 2 months since completing primary vaccination AND you are
	Age 12+	Age 18+	Age 18+
	Pfizer-Buhlfech* Moderna Janson (JSJ) *Ost Piser-Bartles can be aver a si averte in tree aver	Moderna Pflae-BiohGioch Janssen (JMJ)	Janssen (JBJ) Pfloer-BioNTech Moderna

- The recommended dose of the Moderna COVID-19 vaccine for a single booster dose in individuals 18 years of age and older is 0.25 mL intramuscularly (IM) administered at least 5 months after completing a primary series.
 - The primary series for the Moderna COVID-19 vaccine is given as 2 doses of 0.5 mL IM 28 days apart.

What's Next:

• The CDC Director must approve the recommendations before they become official, and she is expected to do so soon



optumrx.com

OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.